Skip to content

Sarepta Therapeutics, Inc. SRPT Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$0
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Sarepta Therapeutics, Inc.'s preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
Sarepta Therapeutics, Inc. (SRPT) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.